<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985526</url>
  </required_header>
  <id_info>
    <org_study_id>33-196 ex 20/21</org_study_id>
    <nct_id>NCT04985526</nct_id>
  </id_info>
  <brief_title>Skin Microbiome and Polymorphic Light Eruption</brief_title>
  <acronym>PLE_microbio</acronym>
  <official_title>The Significance of the Skin Microbiome in the Pathophysiology of Polymorphic Light Eruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polymorphic light eruption (PLE) is the most common form among UV-inducible disorders with a&#xD;
      prevalence of approximately 11-21% worldwide and a clear predisposition of women. Usually,&#xD;
      within several hours after an intense UV exposure, most likely in spring or early summer, the&#xD;
      formation of itchy skin lesions particularly at the upper arms and V-neck and neck is&#xD;
      distinctive for PLE. It has been suggested that the development of a potential photo-induced&#xD;
      antigen may initiate a delayed-type hypersensitivity reaction in PLE (causing the skin rash)&#xD;
      and the microbiota of the skin may be involved. We thus hypothesized that eliminating the&#xD;
      microbiota of the skin by disinfection may affect the formation of PLE. The concept of this&#xD;
      study covers a combined interindividual and intraindividual half-body comparison of the skin&#xD;
      reactions of disinfected and contralateral non-disinfected areas upon UV exposure in PLE&#xD;
      patients and healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      UV-induced erythema and pigmentation is quantified by visual scoring and reflectance&#xD;
      spectroscopy to determine the minimum erythema dose (MED) exploring the fields of an UV test&#xD;
      ladder on the dorsal skin of the study subjects.&#xD;
&#xD;
      Investigations after determining the MED and consecutive photo provocations on 4 subsequent&#xD;
      days (PLE group only) using solar simulated UV radiation with slight dose increments include&#xD;
      a half-body site comparison of test areas located on the back of the subjects in a&#xD;
      randomized, double blinded manner. The microbiota of a respective test area is removed by the&#xD;
      disinfection with Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) whereas a&#xD;
      control site remains non-disinfected (sham-treated with physiologic sodium chloride&#xD;
      solution).&#xD;
&#xD;
      The PLE related symptoms are evaluated by a validated PLE score, which is composed as&#xD;
      follows:&#xD;
&#xD;
      Affected skin area (AA) [range, 0-4] + skin infiltration (SI) [range, 0-4] + 0.4 pruritus (P)&#xD;
      [range, 0-10]; ([total range 0-12].&#xD;
&#xD;
      As additional procedures, tape strips and skin swabs are taken immediately after UV&#xD;
      exposures. The material is used for shotgun metagenomic sequencing of microbes and further&#xD;
      analysis such as quantitative measures of antimicrobial peptides and urocanic acid levels.&#xD;
      Furthermore, suction blisters are produced after MED testing and the last day of photo&#xD;
      provocation [Time Frame: At day 3 and 6] to profile the inflammatory milieu of the skin by&#xD;
      transcriptomics. The epidermal blister roof is used together with optional skin biopsies (PLE&#xD;
      patients only) for various investigations, including H/E and immunohistochemical stainings&#xD;
      and messenger ribonucleic acid (mRNA) analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of PLE</measure>
    <time_frame>1 week</time_frame>
    <description>determined by PLE score (range, 0-12) of photo provocation results (0 best, 12 worst)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of erythema score (range, 0-4)</measure>
    <time_frame>1 week</time_frame>
    <description>determined by visual and spectroscopic erythema score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of pigmentation (range, 0-4)</measure>
    <time_frame>1 week</time_frame>
    <description>determined by visual and spectroscopic erythema score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of multiple cytokines (panel of 96 cytokines)</measure>
    <time_frame>1 week</time_frame>
    <description>determined by transcriptomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of multiple microbiomes of the skin (quantity and variety)</measure>
    <time_frame>1 week</time_frame>
    <description>determined by metagenomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of quantity and quality of multiple Antimicrobial peptides (AMP)</measure>
    <time_frame>1 week</time_frame>
    <description>determined by proteomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of concentration of cis/trans-urocanic acid</measure>
    <time_frame>1 week</time_frame>
    <description>determined by high pressure liquid chromotography (HPLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of cellular skin infiltration (T cells, granulocytes and macrophages)</measure>
    <time_frame>1 week</time_frame>
    <description>determined by hematoxylin and eosin (H/E) and immunohistochemical stainings</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Polymorphic Light Eruption</condition>
  <arm_group>
    <arm_group_label>Polymorphic light eruption patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PLE patients subjected to MED testing and photoprovocation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Normal healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)</intervention_name>
    <description>Administering Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol) or 0,9% sodium chloride (as control agent) to the skin</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Polymorphic light eruption patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of PLE by typical patient history, typical histology of skin&#xD;
             lesions and/or positive photo provocation test&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of malignant skin tumors; dysplastic melanocytic nevus syndrome&#xD;
&#xD;
          -  Photosensitive diseases such as porphyria, chronic actinic dermatitis, xeroderma&#xD;
&#xD;
          -  pigmentosum, basal cell nevus syndrome&#xD;
&#xD;
          -  Autoimmune disorders such as lupus erythematosus or dermatomyositis&#xD;
&#xD;
          -  Antinuclear antibodies titer over 1:160 within 12 months prior study&#xD;
&#xD;
          -  Systemic treatment of steroids and/or immunosuppressive drugs within 4 weeks prior the&#xD;
             study start&#xD;
&#xD;
          -  Systemic treatment of antibiotics within the last 6 weeks prior study&#xD;
&#xD;
          -  Local treatment of anti-microbial treatment in the test field area within the last 6&#xD;
             weeks prior the study&#xD;
&#xD;
          -  Systemic treatment of medications/drugs/ that could affect inflammatory responses&#xD;
             within 2 weeks prior study&#xD;
&#xD;
          -  Allergy on tape strips and/or adhesive material&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Wolf, MD</last_name>
    <phone>0043 316 385</phone>
    <phone_ext>80315</phone_ext>
    <email>peter.wolf@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maximilian Zarfl</last_name>
    <phone>00 43 660 6682953‬</phone>
    <email>maximilian.zarfl@stud.medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wolf</last_name>
      <phone>031638580315</phone>
      <email>peter.wolf@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Maximilian Zarfl</last_name>
      <phone>00 43 660 6682953‬</phone>
      <email>maximilian.zarfl@stud.medunigraz.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exanthema</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octenidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

